Clinical Trials on Refractory and Relapsed Primary CNS Lymphoma

Total 11797 results

Princess Maxima Center for Pediatric Oncology
Innovative Therapies For Children with Cancer Consortium; IBFM; Fight Kids Cancer

Withdrawn

HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies (HEM-iSMART A)

Acute Lymphoblastic Leukemia, in Relapse | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory

Netherlands
Sun Yat-sen University

Recruiting

Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)

Follicular Lymphoma | Relapsed and Refractory Follicular Lymphoma

China
James Rubenstein
Genentech, Inc.; Celgene

Completed

Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma

Intraocular Lymphoma | Recurrent/Refractory CNS

United States
Fred Hutchinson Cancer Center
Faron Pharmaceuticals Ltd

Not yet recruiting

Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory Mantle Cell Lymphoma

United States
Northwestern University
National Cancer Institute (NCI)

Recruiting

Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma

Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Recurrent... and other conditions

United States
NeoImmuneTech

Recruiting

Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Refractory High Grade B-Cell Lymphoma | Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-cell Lymphoma

United States
University of Washington
Bristol-Myers Squibb

Active, not recruiting

Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory Plasma Cell Myeloma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma and other conditions

United States
Juno Therapeutics, Inc., a Bristol-Myers Squibb...
Celgene Corporation

Not yet recruiting

A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma

Relapsed or Refractory Follicular Lymphoma
Hoffmann-La Roche

Recruiting

A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma (Celestimo)

Relapsed or Refractory Follicular Lymphoma

United States, Korea, Republic of, Taiwan, China, Spain, United Kingdom, Australia, France, Germany, Japan, Turkey, Brazil, Poland, Ukraine, Italy, Russian Federation
Genta Incorporated

Completed

Phase II Gallium Nitrate in Relapsed or Refractory Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma | Refractory Lymphoma | Relapsed Lymphoma | Low-Grade Lymphoma | Intermediate-Grade Lymphoma

United States
Xijing Hospital
Xi'An Yufan Biotechnology Co.,Ltd

Recruiting

CRISPR (HPK1) Edited CD19-specific CAR-T Cells (XYF19 CAR-T Cells) for CD19+ Leukemia or Lymphoma.

Lymphoma, B-Cell | CD19 Positive | Leukemia Lymphocytic Acute (ALL) in Relapse | Leukemia Lymphocytic Acute (All) Refractory

China
ADC Therapeutics S.A.

Completed

Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma

Refractory Hodgkin Lymphoma | Relapsed Hodgkin Lymphoma

United States, Spain, United Kingdom, Poland, Belgium, Hungary, Germany, France, Italy, Czechia, Canada
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies

Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma | Recurrent Transformed Chronic Lymphocytic Leukemia | Refractory...

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Refractory Mantle Cell Lymphoma

United States
The First Affiliated Hospital of Xiamen University
The First Affiliated Hospital with Nanjing Medical University; Shanxi Province... and other collaborators

Recruiting

Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma

Follicular Lymphoma | Relapsed Non-Hodgkin Lymphoma | Refractory B-Cell Lymphoma

China
National Cancer Institute (NCI)

Completed

Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma With... and other conditions

United States
Marker Therapeutics, Inc.

Recruiting

Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma (APOLLO)

Hodgkin Lymphoma | Non Hodgkin Lymphoma | Hodgkin Lymphoma, Adult | Non-Hodgkin Lymphoma, Adult | Non-Hodgkin Lymphoma, Refractory | Non-Hodgkin Lymphoma, Relapsed | Hodgkin's Lymphoma, Relapsed, Adult

United States
Jonsson Comprehensive Cancer Center

Recruiting

Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma

Progressive Disease | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma | Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | Refractory High Grade B-Cell Lymphoma | Refractory Transformed Follicular... and other conditions

United States
Children's Mercy Hospital Kansas City

Completed

Low Dose Daunorubicin in Pediatric Relapsed/Refractory Acute Leukemia

Refractory Acute Myeloid Leukemia | Refractory Acute Lymphoblastic Leukemia | Relapsed Pediatric AML | Relapsed Pediatric ALL

United States
Ohio State University Comprehensive Cancer Center

Active, not recruiting

Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma and other conditions

United States
Hutchison Medipharma Limited

Recruiting

Tazemetostat for the Treatment of Relapsed/Refractory Follicular Lymphoma

Relapsed/Refractory Follicular Lymphoma With EZH2

China
ImmunityBio, Inc.

Not yet recruiting

Study for Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma Refractory/ Relapsed
Bristol-Myers Squibb

Recruiting

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

Relapsed/Refractory Non-Hodgkin Lymphoma

United States, Spain, France, Netherlands, Switzerland
AbbVie
Genentech, Inc.

Withdrawn

A Pharmacokinetic Study to Access How the Body Absorbs and Removes ABT-199 in Adults With Non-Hodgkin's Lymphoma

Relapsed/Refractory Non-Hodgkin's Lymphoma
SIRPant Immunotherapeutics, Inc.

Recruiting

Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma

Refractory Non-Hodgkin Lymphoma | Relapsed Non-Hodgkin Lymphoma

United States
Fate Therapeutics

Recruiting

FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)

Relapsed/Refractory B-Cell Lymphoma

United States
Kite, A Gilead Company

Active, not recruiting

Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3) (ZUMA-2)

Relapsed/Refractory Mantle Cell Lymphoma

United States, France, Spain, United Kingdom, Netherlands, Germany
La Raza Medical Center

Completed

Outpatient Administration of R-DHAP in Relapsed/Refractory Non-Hodgkin Lymphoma

Refractory Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma

Mexico
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Gilead Sciences; Celgene Corporation; Biologics...

Completed

Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Relapsed/Refractory Mantle Cell Lymphoma

United States
Daiichi Sankyo

Active, not recruiting

Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

Relapsed/Refractory Peripheral T-Cell Lymphoma | Adult T Cell Leukemia/Lymphoma

United States, Spain, Japan, United Kingdom, Korea, Republic of, France, Italy, Australia, Canada, Germany, Netherlands, Taiwan
Adam Kittai

Recruiting

Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome

Recurrent Transformed Non-Hodgkin Lymphoma | Recurrent Transformed B-Cell Non-Hodgkin Lymphoma | Refractory Transformed Non-Hodgkin Lymphoma | Refractory Transformed B-cell Non-Hodgkin Lymphoma | Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma | Recurrent Transformed... and other conditions

United States
Thomas Jefferson University
National Cancer Institute (NCI)

Recruiting

An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment

Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Indolent Adult Non-Hodgkin Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Refractory Marginal Zone Lymphoma | Recurrent Indolent Adult Non-Hodgkin...

United States
Brian Hill

Recruiting

Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma

Refractory Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma

United States
The First Affiliated Hospital of Soochow University
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

Unknown

A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma

Refractory Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma

China
The Lymphoma Academic Research Organisation
Celgene Corporation

Completed

A Phase IB Study Of The BTKi CC-292 Combined With Lenalidomide In Adults Patients With Relapsed/Refractory B-Cell Lymphoma (CLEAR)

Relapsed/Refractory B-cell Lymphoma

France
Second Affiliated Hospital, School of Medicine,...

Recruiting

Exploratory Clinical Study of CD19-targeted CAR-T and CAR-DC in the Treatment of Relapsed and Refractory B-cell Lymphoma

Relapsed and Refractory B-cell Lymphoma

China
AHS Cancer Control Alberta
Tom Baker Cancer Centre

Terminated

GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory Lymphoma (GEMHDM2014)

Follicular Lymphoma | Hodgkin's Lymphoma - Relapsed/Refractory | Non-Hodgkin's Lymphoma - Aggressive

Canada
Mustang Bio

Enrolling by invitation

Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.

Diffuse Large B Cell Lymphoma | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Hairy Cell Leukemia | Mantle Cell Lymphoma Recurrent | Mantle Cell Lymphoma Refractory | Chronic Lymphocytic Leukemia in Relapse | Small Lymphocytic Lymphoma, Relapsed | Waldenstrom's Macroglobulinemia Recurrent | Follicular B-cell Non-Hodgkin's Lymphoma and other conditions

United States
ImmunityBio, Inc.

Recruiting

Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma

Non Hodgkin's Lymphoma Refractory/Relapsed

United States
Shandong Provincial Hospital

Unknown

Study of PD-1 Monoclonal Antibody in Combination With Chemotherapy in Patients With RR NHL

Relapsed/Refractory Non-Hodgkin's Lymphoma

China
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Radiation Therapy Before CAR T Cell Therapy for People With B Cell Lymphoma

Non-Hodgkin Lymphoma | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma Refractory

United States
Korea Cancer Center Hospital

Unknown

131I-rituximab for Relapsed or Refractory Follicular or Mantle Cell Lymphoma

Relapsed or Refractory Follicular Lymphoma or Mantle Cell Lymphoma

Korea, Republic of
Fondazione Italiana Linfomi - ETS

Recruiting

Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients. (FIL_COLUMN)

Refractory Mantle Cell Lymphoma | Relapsed Mantle Cell Lymphoma

Italy
National Cancer Institute (NCI)

Active, not recruiting

Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Recurrent Grade 3a Follicular Lymphoma | Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Recurrent Mycosis Fungoides | Recurrent Primary Cutaneous... and other conditions

United States, Canada
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

To Evaluate the Safety and Efficacy of TQB2618 Injection Combined With Penpulimab in the Treatment of Patients With Relapsed and Refractory Lymphoma

Relapsed/Refractory Lymphoma

China
Shandong New Time Pharmaceutical Co., LTD

Not yet recruiting

Study of F527 in Patients With Relapsed or Refractory Lymphoma

Relapsed/Refractory Lymphoma

China
The First Affiliated Hospital of Soochow University
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

Recruiting

A Study of ASCT Bridging CART Cell Therapy in Relapsed/Refractory B-cell Lymphoma

Refractory Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma

China
Kite, A Gilead Company

Completed

Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2) (ZUMA-2)

Relapsed/Refractory Mantle Cell Lymphoma

United States, Netherlands, Germany, France
Joseph Tuscano
Spectrum Pharmaceuticals, Inc

Active, not recruiting

Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

Relapsed Non Hodgkin Lymphoma | Refractory Non Hodgkin Lymphoma

United States
GC Cell Corporation

Unknown

MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin

Refractory Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma

Korea, Republic of

Clinical Trials on Refractory and Relapsed Primary CNS Lymphoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Africa

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations